Groupe la Francaise Has $6.61 Million Stock Position in Stryker Corporation $SYK

Groupe la Francaise boosted its stake in Stryker Corporation (NYSE:SYK) by 16.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,000 shares of the medical technology company’s stock after buying an additional 3,000 shares during the quarter. Groupe la Francaise’s holdings in Stryker were worth $6,613,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in shares of Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP raised its position in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new stake in shares of Stryker during the second quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker during the second quarter valued at $253,000. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SYK. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. cut their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. Piper Sandler decreased their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, UBS Group began coverage on Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $302.92 on Tuesday. The business has a 50 day simple moving average of $328.30 and a 200 day simple moving average of $329.01. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.37. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market cap of $116.19 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 1.90 and a beta of 0.76.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts anticipate that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.